The Clinical Significance of High Antimicrobial Resistance in Community-Acquired Urinary Tract Infections
- PMID: 32566057
- PMCID: PMC7293720
- DOI: 10.1155/2020/2967260
The Clinical Significance of High Antimicrobial Resistance in Community-Acquired Urinary Tract Infections
Abstract
Background: Urinary tract infections (UTIs) affect up to 150 million individuals annually worldwide, mainly due to Escherichia coli (E. coli) and Klebsiella. The emergence and spread of multidrug-resistant (MDR) bacteria are increasing, representing one of the biggest threats for human health. The objective of our study was to describe antimicrobial patterns of resistance and identify risk factors associated with MDR uropathogens.
Methods: We conducted a cross-sectional study in 296 patients with community-acquired UTI who underwent clinical and microbiologic analysis, and clinical associations to MDR uropathogens were investigated. Findings. Microbiological analysis included E. coli (55%), ESBL-E. coli (26%), Enterococcus (6%), Klebsiella (5%), and others (8%). Higher frequencies of MDR bacteria were found among ESBL-E. coli, with resistance to ampicillin (100%), ceftriaxone (96%), gentamicin (57%), ciprofloxacin (89%), and TMP/SMX (53%). However, they were sensitive to fosfomycin (6.6%), nitrofurantoin (1.3%), and carbapenems (0%). Fosfomycin MIC90 for ESBL-E. coli was 5.78 μg/mL. The only clinical variable with significant association to ESBL producers was the presence of comorbidities: hypertension and type 2 diabetes mellitus with an OR (95%CI) of 2.5(1.3 - 4.9)(p < 0.01) and 2.8(1.2 - 6.7)(p < 0.05), respectively.
Conclusions: In the majority of cases, resistance rates to commonly prescribed antimicrobials in UTIs were high, except for fosfomycin, nitrofurantoin, and carbapenems. To provide appropriate treatment, both the identification of risk factors and the uropathogen would be important. An active surveillance in UTIs in the community is required since the proportion of ESBL producers is increasing.
Copyright © 2020 Maria G. Zavala-Cerna et al.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Fosfomycin susceptibility in multidrug resistant uropathogens: A retrospective study in the era of antimicrobial resistance.J Family Med Prim Care. 2025 Apr;14(4):1346-1351. doi: 10.4103/jfmpc.jfmpc_1074_24. Epub 2025 Apr 25. J Family Med Prim Care. 2025. PMID: 40396075 Free PMC article.
-
Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.Int Urol Nephrol. 2015 Jul;47(7):1059-66. doi: 10.1007/s11255-015-1018-9. Epub 2015 May 31. Int Urol Nephrol. 2015. PMID: 26026972
-
Bacteria Causing Community-Acquired Urinary Tract Infections and Their Antibiotic Susceptibility Patterns in Outpatients Attending at a State Hospital in Turkey.Cureus. 2021 Sep 6;13(9):e17753. doi: 10.7759/cureus.17753. eCollection 2021 Sep. Cureus. 2021. PMID: 34659966 Free PMC article.
-
Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.Postgrad Med. 2020 Apr;132(3):234-250. doi: 10.1080/00325481.2019.1680052. Epub 2019 Oct 24. Postgrad Med. 2020. PMID: 31608743 Review.
-
An update on the management of urinary tract infections in the era of antimicrobial resistance.Postgrad Med. 2017 Mar;129(2):242-258. doi: 10.1080/00325481.2017.1246055. Epub 2016 Oct 21. Postgrad Med. 2017. PMID: 27712137 Review.
Cited by
-
Causative Microorganisms in Community-Acquired Urinary Tract Infections and Risk Factors for the Development of Infection with Extended-Spectrum β-Lactamase-Producing Species.Infect Dis Clin Microbiol. 2024 Jun 28;6(2):112-122. doi: 10.36519/idcm.2024.340. eCollection 2024 Jun. Infect Dis Clin Microbiol. 2024. PMID: 39005695 Free PMC article.
-
Combating antimicrobial resistance with cefiderocol for complicated infections involving the urinary tract.Ther Adv Urol. 2022 Jan 31;14:17562872211065570. doi: 10.1177/17562872211065570. eCollection 2022 Jan-Dec. Ther Adv Urol. 2022. PMID: 35126672 Free PMC article. Review.
-
Therapeutic strategies for uncomplicated cystitis in women.GMS Infect Dis. 2024 Apr 29;12:Doc01. doi: 10.3205/id000086. eCollection 2024. GMS Infect Dis. 2024. PMID: 38764941 Free PMC article. Review.
-
Amidochelocardin Overcomes Resistance Mechanisms Exerted on Tetracyclines and Natural Chelocardin.Antibiotics (Basel). 2020 Sep 18;9(9):619. doi: 10.3390/antibiotics9090619. Antibiotics (Basel). 2020. PMID: 32962088 Free PMC article.
-
Uropathogenic E. coli and Hybrid Pathotypes in Mexican Women with Urinary Tract Infections: A Comprehensive Molecular and Phenotypic Overview.Curr Issues Mol Biol. 2024 Jun 13;46(6):5909-5928. doi: 10.3390/cimb46060353. Curr Issues Mol Biol. 2024. PMID: 38921024 Free PMC article.
References
-
- Ferry S. A., Holm S. E., Stenlund H., Lundholm R., Monsen T. J. Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project. Scandinavian Journal of Primary Health Care. 2007;25(1):49–57. doi: 10.1080/02813430601183074. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources